Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pharming Group N.V. ADR (PHAR)

Pharming Group N.V. ADR (PHAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 562,322
  • Shares Outstanding, K 67,344
  • Annual Sales, $ 245,320 K
  • Annual Income, $ -10,550 K
  • 60-Month Beta 0.18
  • Price/Sales 2.16
  • Price/Cash Flow 80.64
  • Price/Book 2.56
Trade PHAR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.20
  • Low Estimate -0.20
  • Prior Year 0.02
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.97 +19.08%
on 06/21/24
10.00 -17.00%
on 06/06/24
-0.85 (-9.29%)
since 05/31/24
3-Month
6.97 +19.08%
on 06/21/24
11.30 -26.55%
on 04/11/24
-2.99 (-26.45%)
since 04/01/24
52-Week
6.97 +19.08%
on 06/21/24
16.71 -50.33%
on 09/21/23
-3.35 (-28.76%)
since 06/30/23

Most Recent Stories

More News
Pharming Group to participate in September investor conferences

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the...

PHAR : 8.26 (-1.08%)
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled...

PHAR : 8.26 (-1.08%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 8.26 (-1.08%)
KA : 0.5307 (-6.89%)
APRE : 4.07 (-0.49%)
XFOR : 0.6120 (+5.52%)
Pharming Group to report second quarter and first half 2023 financial results on August 3

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter...

PHAR : 8.26 (-1.08%)
Pharming announces sale of priority review voucher

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive...

PHAR : 8.26 (-1.08%)
Pharming Group to attend the following Investor Conferences in June

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will attend the following...

PHAR : 8.26 (-1.08%)
Pharming Group reports financial results for the first quarter of 2023

FDA approval and commercial launch of Joenja® (leniolisib) in the U.S. Joenja® launch off to strong start with 23 U.S. patients on paid therapy Revenues...

PHAR : 8.26 (-1.08%)
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries...

PHAR : 8.26 (-1.08%)
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that Pharming's Chief Executive Officer, Sijmen de Vries...

PHAR : 8.26 (-1.08%)
Notice of First Quarter 2023 Results

/PRNewswire/ -- Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) confirms it will announce first quarter 2023 financial results for...

PHAR : 8.26 (-1.08%)

Business Summary

Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The company's product portfolio includes C1INH. Pharming Group N.V. is based in Leiden, The Netherlands....

See More

Key Turning Points

3rd Resistance Point 8.94
2nd Resistance Point 8.65
1st Resistance Point 8.50
Last Price 8.26
1st Support Level 8.05
2nd Support Level 7.76
3rd Support Level 7.61

See More

52-Week High 16.71
Fibonacci 61.8% 12.99
Fibonacci 50% 11.84
Fibonacci 38.2% 10.69
Last Price 8.26
52-Week Low 6.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar